Brokers Offer Predictions for MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.70) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2027 earnings at ($0.82) EPS, Q3 2027 earnings at ($0.91) EPS and Q4 2027 earnings at ($0.67) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share for the quarter, meeting the consensus estimate of ($0.92). During the same period in the prior year, the company posted ($0.72) EPS.

MLTX has been the subject of a number of other reports. The Goldman Sachs Group downgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and increased their price target for the company from $8.00 to $10.00 in a report on Wednesday, January 14th. Needham & Company LLC boosted their price objective on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. UBS Group set a $24.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Friday, January 9th. Oppenheimer increased their target price on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Finally, Rothschild & Co Redburn raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $12.00 to $40.00 in a research report on Thursday, March 19th. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, MoonLake Immunotherapeutics has an average rating of “Hold” and a consensus target price of $23.08.

MoonLake Immunotherapeutics Stock Down 11.4%

Shares of MLTX stock opened at $16.52 on Tuesday. MoonLake Immunotherapeutics has a 12 month low of $5.95 and a 12 month high of $62.75. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. The firm has a market cap of $1.18 billion, a PE ratio of -4.69 and a beta of 1.19. The stock has a 50 day moving average of $16.91 and a 200-day moving average of $16.88.

Institutional Trading of MoonLake Immunotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Elevation Point Wealth Partners LLC acquired a new position in MoonLake Immunotherapeutics in the second quarter worth about $74,000. Kestra Advisory Services LLC acquired a new stake in MoonLake Immunotherapeutics during the fourth quarter valued at approximately $26,000. Russell Investments Group Ltd. grew its stake in shares of MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after purchasing an additional 1,069 shares during the period. T. Rowe Price Investment Management Inc. bought a new stake in MoonLake Immunotherapeutics in the fourth quarter valued at $47,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at $28,000. Institutional investors own 93.85% of the company’s stock.

Key MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: BTIG reaffirmed its Buy rating on MoonLake, keeping institutional support that can attract momentum investors. BTIG Research Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
• Positive Sentiment: H.C. Wainwright reiterated a Buy on MLTX and continues to use a $40 price target, reinforcing a favorable sell‑side view and a high upside reference point for investors. H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
• Positive Sentiment: MLTX has drawn retail attention from buyout speculation and release of positive skin‑condition trial data — a near‑term catalyst that likely lifted volume and interest even as volatility increased. MLTX stock garners retail attention on buyout speculation, positive skin condition trial data
• Neutral Sentiment: H.C. Wainwright published quarterly EPS forecasts for 2027 (Q1–Q4) showing continued per‑share losses (e.g., quarterly EPS guides around -$0.70 to -$0.91) while maintaining its Buy stance — useful for modeling near‑term cash burn but not a rating change. HC Wainwright estimates for MoonLake Immunotherapeutics (MarketBeat)
• Neutral Sentiment: MarketWatch’s cash‑flow/financials page provides the company’s liquidity metrics and financials that investors should review — MoonLake shows ample current/quick ratios and modest leverage, which may support runway. MoonLake Immunotherapeutics cash flow (MarketWatch)
• Negative Sentiment: MoonLake reported continuing GAAP losses (recent quarter EPS ~ -$0.92, matching estimates but worse year‑over‑year) and the street expects full‑year negative EPS — a reminder that the company is not yet profitable and remains dependent on funding or positive clinical outcomes. MoonLake financial summary and analyst consensus (MarketBeat)

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.